EBMT 2021 | EBMT 2021 highlights: CAR-NK
Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, shares his highlights from EBMT, discussing the use of natural killer (NK) cells for cellular therapy. Dr Grupp describes how new research has demonstrated that cord blood could be used to make chimeric antigen receptor (CAR)-NK cells. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Dr Stephan Grupp, MD, PhD, has received research support from Novartis, Servier, Vertex and Kite; and has participated in study steering committees, consulting, or scientific advisory boards with Novartis, Allogene, Adaptimmune, TCR2, Cabaletta, Juno, CBMG, GlaxoSmithKline, Cellectis, Johnson & Johnson/Janssen, CRISPR/Vertex, Roche, Humanigen and Jazz.
